Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > LATEST
LATEST
-
BUSINESS Japan Ethical Drug Sales Fall 1.1% in May: Crecon
July 8, 2026
-
REGULATORY LDP, Ishin Near Deal on Chuikyo Reform to Bolster Drug Discovery
July 7, 2026
-
BUSINESS Astellas Confirms Applying to US MFN Medicaid Pricing Model
July 7, 2026
-
REGULATORY Govt Eyes Honebuto Revisions on Biosimilars, MFN Policy
July 7, 2026
-
BUSINESS Otsuka’s Astex Inks Breast Cancer R&D Pact with Genentech
July 7, 2026
-
REGULATORY JMA Chief Calls for Subsidies, Tax Breaks to Boost Domestic Drug Production
July 7, 2026
-
REGULATORY LDP Launches Alzheimer’s League, Experts Call for Earlier Intervention
July 7, 2026
-
BUSINESS Ribomic, Fujifilm to Join Forces on LNP CDMO Services
July 7, 2026
-
BUSINESS Toray Unveils Next-Generation Opioid Painkiller Candidate
July 7, 2026
-
BUSINESS Keytruda’s No. 1 Streak Reaches 33 Months: Encise
July 7, 2026
-
BUSINESS Takeda Rolls Out Higher-Concentration Kenketu Glovenin-I 10%
July 7, 2026
-
ORGANIZATION Labor Group Urges Govt to Scrap FY2027 Off-Year Drug Price Cuts
July 7, 2026
-
COMMENTARY DORA Use Could Expand as Japan Opens Door to “Sleep Disorders” Specialty
July 6, 2026
-
BUSINESS Tanabe to Sell Manufacturing Unit to Towa, Transfer 17 Products
July 6, 2026
-
ORGANIZATION Japan’s Contract Rep Workforce Hits Record High in FY2025
July 6, 2026
-
BUSINESS Espha Launches Generic Forxiga; Nipro AG Due in September
July 6, 2026
-
ORGANIZATION Japan’s Generic Use Rate Climbs to 89.7% in FY2025: JGA
July 6, 2026
-
REGULATORY Japan, US Launch Talks on Pharma GMP MRA to Ease Inspection Burden
July 3, 2026
-
BUSINESS GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
-
REGULATORY MHLW Gives Kissei until July 21 to Report on Tavneos
July 3, 2026
ページ
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…